TNG.F Tong Ren Tang Technologies Co. Ltd
- Market cap
- EUR 415M
- P/E
- 10.8x
- P/B
- 0.42x
- ROE
- 5.4%
- Dividend yield
- 7.09%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is TNG.F undervalued?
Graham numberTNG.F trades 55.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tong Ren Tang Technologies Co. Ltd fundamental analysis
No fundamental analysis for Tong Ren Tang Technologies Co. Ltd yet.
Tong Ren Tang Technologies Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tong Ren Tang Technologies Co. Ltd
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others. The company develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products. It also offers ointments, healthcare products, tea drinks, food, fo…
Full company profileTong Ren Tang Technologies Co. Ltd financial statements
Tong Ren Tang Technologies Co. Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.67B | 5.03B | 5.06B | 4.48B | 4.61B | 5.40B | 5.99B | 6.77B | 7.26B | 6.48B |
| Gross Profit | 2.37B | 2.53B | 2.43B | 2.05B | 2.07B | 2.29B | 2.59B | 2.85B | 2.88B | 2.47B |
| Operating Income | 1.01B | 1.17B | 1.20B | 938M | 966M | 1.07B | 1.20B | 1.13B | 985M | 802M |
| EBITDA | - | 1.27B | 1.31B | 1.12B | 991M | 1.11B | 1.53B | 1.49B | 1.42B | 1.22B |
| Net Income | 596M | 667M | 678M | 418M | 468M | 507M | 583M | 590M | 522M | 396M |
| EPS | - | 0.52 | 0.53 | 0.33 | 0.37 | 0.40 | 0.46 | 0.46 | 0.41 | 0.31 |
| Balance Sheet | ||||||||||
| Total Assets | 8.18B | 8.88B | 9.77B | 10.5B | 10.9B | 11.6B | 12.5B | 13.5B | 14.4B | 13.7B |
| Total Liabilities | 2.30B | 2.42B | 2.49B | 3.06B | 3.19B | 3.44B | 3.47B | 3.86B | 4.24B | 3.45B |
| Shareholders' Equity | 4.40B | 4.82B | 5.32B | 5.53B | 5.73B | 5.98B | 6.48B | 6.89B | 7.21B | 7.34B |
| Cash & Short-term Investments | 2.33B | 2.02B | 1.90B | 2.99B | 2.95B | 3.25B | 3.72B | 2.75B | 4.13B | 4.70B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 410M | 680M | 985M | 1.05B | 436M | 1.03B | 724M | 554M | 15.6M | 1.56B |
| Capital Expenditure | 436M | 412M | 357M | 210M | 546M | 156M | 158M | 103M | 174M | 117M |
| Free Cash Flow | - | 255M | 613M | 783M | -336M | 877M | 560M | 451M | -159M | 1.45B |
| Ratios | ||||||||||
| ROE | 13.5% | 13.8% | 12.7% | 7.6% | 8.2% | 8.5% | 9.0% | 8.6% | 7.2% | 5.4% |
| ROA | 7.3% | 7.5% | 6.9% | 4.0% | 4.3% | 4.4% | 4.7% | 4.4% | 3.6% | 2.9% |
| Net Profit Margin | 12.8% | 13.3% | 13.4% | 9.3% | 10.1% | 9.4% | 9.7% | 8.7% | 7.2% | 6.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Tong Ren Tang Technologies Co. Ltd dividends
- Dividend yield
- 7.09%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 57.6%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 228M | 0.18 | 57.6% |
| 2024 | CNY 228M | 0.18 | 43.7% |
| 2023 | CNY 203M | 0.16 | 34.4% |
| 2022 | CNY 205M | 0.16 | 35.2% |
| 2021 | CNY 205M | 0.16 | 40.4% |
| 2020 | CNY 205M | 0.16 | 43.8% |
| 2019 | EUR 231M | 0.18 | 55.2% |
| 2018 | EUR 218M | 0.17 | 32.1% |
| 2017 | EUR 205M | 0.16 | 30.7% |
| 2016 | EUR 192M | - | 32.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 17, 2014.
Who owns Tong Ren Tang Technologies Co. Ltd
- Insiders 6.90%
- Institutions 14.30%
- Public & others 78.80%
- Shares outstanding 629M
- Free float 585M
Tong Ren Tang Technologies Co. Ltd company profile
- Company name
- Tong Ren Tang Technologies Co. Ltd
- Ticker
- TNG.F
- ISIN
- CNE100000585
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,801
- Fiscal year end
- December
- Address
- No. 20 Nansanhuan Zhonglu Road, Beijing, China, 100079
- Phone
- 86 10 8763 2888
- Website
- tongrentangkj.com
About Tong Ren Tang Technologies Co. Ltd
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others. The company develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products. It also offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China.
Tong Ren Tang Technologies Co. Ltd management
6- Mr. Yi ZhangExecutive Chairman of the Board · born 1976
- Mr. Chun You ZhangGM & Executive Director · born 1968
- Ms. Kai Ting WenExecutive Director · born 1978
- Mr. Guan Zhao HanDeputy GM, Chief Compliance Officer & General Legal Counsel · born 1980
- Ms. Wing Yee MaCompany Secretary
- Ms. Zhe MeiJoint Company Secretary · born 1989